We are analyzing https://link.springer.com/article/10.1186/s40425-017-0218-5.

Title:
Combination immunotherapy: a road map | Journal for ImmunoTherapy of Cancer
Description:
Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action. In order to address the current progress and consider challenges associated with these novel approaches, the Society for Immunotherapy of Cancer (SITC) convened a Combination Immunotherapy Task Force. This Task Force was charged with identifying and prioritizing the most promising prospects for combinatorial approaches as well as addressing the challenges associated with developing these strategies. As a result of the extensive clinical benefit and tolerable side effects demonstrated with agents inhibiting the PD-1 pathway, an overview of current evidence to support its promising potential for use as a backbone in combination strategies is presented. In addition, key issues in the development of these strategies including preclinical modeling, patient safety and toxicity considerations, clinical trial design, and endpoints are also discussed. Overall, the goal of this manuscript is to provide a summary of the current status and potential challenges associated with the development and clinical implementation of these strategies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, combination, article, google, scholar, tumor, cancer, cas, patients, clinical, melanoma, cell, immune, cells, immunotherapy, ipilimumab, models, activity, central, mice, development, response, dose, inhibition, nivolumab, agents, safety, tumors, blockade, monotherapy, combinations, mouse, potential, ctla, therapy, treated, agent, phase, murine, mgkg, med, clin, study, regimens, treatment, model, including, preclinical, responses, combined,

Topics {✒️}

granulocyte/macrophage colony-stimulating factor mild graft-versus-host disease tumor-draining lymph nodes anti-pd-1/pd-l1 monotherapy anti-il-6 anti-cytokine antibodies pd-1/pd-l1 blockade immunotherapy single agent anti-pd-1/pd potent immune-stimulating target immune-related adverse events chimeric antigen receptor-modified article download pdf anti-pd-l1 antibody require pathogen-free environments specific pathogen-free conditions pre-existent tumor directed tumor-specific ctl reactivity demonstrated long-term survival tumor necrosis factor long-term disease stabilization anti-pd1 therapeutic antibodies impressive anti-tumor activity �zig-zag” approach guided t-cell-dependent mechanism pd-1/pd-l1 backbone immune-related response criteria anti-ctla-4 ab blockade pd-1/pd-l1 blockade genetically-engineered mouse models potent antigen-presenting cells small-cell lung cancer treatment-related discontinuations occurred autoimmune-related side effects pd-1/pd-l1 inhibition synergistic anti-tumor responses cd3-based bispecific agents single-dose radiotherapy induces 12-o-tetradecanoylphorbol-13-acetate treg increased e-selectin expression maximum biologically-effective dose combined pd-1/pd-l1 phase i-iii trials late-stage cancer patients pre-clinical murine models algorithm-based supportive care established anti-tumor activity pre-clinical animal models naive tumor-specific cd4 glucocorticoid-induced tnfr termed immune-checkpoint blockade immune-mediated abscopal effect

Questions {❓}

Experimental mouse tumour models: what can be learnt about human cancer immunology?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Combination immunotherapy: a road map
         description:Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action. In order to address the current progress and consider challenges associated with these novel approaches, the Society for Immunotherapy of Cancer (SITC) convened a Combination Immunotherapy Task Force. This Task Force was charged with identifying and prioritizing the most promising prospects for combinatorial approaches as well as addressing the challenges associated with developing these strategies. As a result of the extensive clinical benefit and tolerable side effects demonstrated with agents inhibiting the PD-1 pathway, an overview of current evidence to support its promising potential for use as a backbone in combination strategies is presented. In addition, key issues in the development of these strategies including preclinical modeling, patient safety and toxicity considerations, clinical trial design, and endpoints are also discussed. Overall, the goal of this manuscript is to provide a summary of the current status and potential challenges associated with the development and clinical implementation of these strategies.
         datePublished:2017-02-21T00:00:00Z
         dateModified:2017-02-21T00:00:00Z
         pageStart:1
         pageEnd:15
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40425-017-0218-5
         keywords:
            Immunotherapy
            Combination
            Checkpoint inhibitors
            Preclinical models
            Clinical trial
            Endpoints
            Oncology
            Immunology
         image:
         isPartOf:
            name:Journal for ImmunoTherapy of Cancer
            issn:
               2051-1426
            volumeNumber:5
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Patrick A. Ott
               affiliation:
                     name:Dana-Farber Cancer Institute, Harvard Medical School
                     address:
                        name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:F. Stephen Hodi
               affiliation:
                     name:Dana-Farber Cancer Institute, Harvard Medical School
                     address:
                        name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Howard L. Kaufman
               affiliation:
                     name:Rutgers Cancer Institute of New Jersey
                     address:
                        name:Rutgers Cancer Institute of New Jersey, New Brunswick, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jon M. Wigginton
               affiliation:
                     name:MacroGenics, Inc.
                     address:
                        name:MacroGenics, Inc., Rockville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jedd D. Wolchok
               affiliation:
                     name:Memorial Sloan Kettering Cancer Center
                     address:
                        name:Memorial Sloan Kettering Cancer Center, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Combination immunotherapy: a road map
      description:Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action. In order to address the current progress and consider challenges associated with these novel approaches, the Society for Immunotherapy of Cancer (SITC) convened a Combination Immunotherapy Task Force. This Task Force was charged with identifying and prioritizing the most promising prospects for combinatorial approaches as well as addressing the challenges associated with developing these strategies. As a result of the extensive clinical benefit and tolerable side effects demonstrated with agents inhibiting the PD-1 pathway, an overview of current evidence to support its promising potential for use as a backbone in combination strategies is presented. In addition, key issues in the development of these strategies including preclinical modeling, patient safety and toxicity considerations, clinical trial design, and endpoints are also discussed. Overall, the goal of this manuscript is to provide a summary of the current status and potential challenges associated with the development and clinical implementation of these strategies.
      datePublished:2017-02-21T00:00:00Z
      dateModified:2017-02-21T00:00:00Z
      pageStart:1
      pageEnd:15
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40425-017-0218-5
      keywords:
         Immunotherapy
         Combination
         Checkpoint inhibitors
         Preclinical models
         Clinical trial
         Endpoints
         Oncology
         Immunology
      image:
      isPartOf:
         name:Journal for ImmunoTherapy of Cancer
         issn:
            2051-1426
         volumeNumber:5
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Patrick A. Ott
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:F. Stephen Hodi
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Howard L. Kaufman
            affiliation:
                  name:Rutgers Cancer Institute of New Jersey
                  address:
                     name:Rutgers Cancer Institute of New Jersey, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jon M. Wigginton
            affiliation:
                  name:MacroGenics, Inc.
                  address:
                     name:MacroGenics, Inc., Rockville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jedd D. Wolchok
            affiliation:
                  name:Memorial Sloan Kettering Cancer Center
                  address:
                     name:Memorial Sloan Kettering Cancer Center, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal for ImmunoTherapy of Cancer
      issn:
         2051-1426
      volumeNumber:5
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Rutgers Cancer Institute of New Jersey
      address:
         name:Rutgers Cancer Institute of New Jersey, New Brunswick, USA
         type:PostalAddress
      name:MacroGenics, Inc.
      address:
         name:MacroGenics, Inc., Rockville, USA
         type:PostalAddress
      name:Memorial Sloan Kettering Cancer Center
      address:
         name:Memorial Sloan Kettering Cancer Center, New York, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Patrick A. Ott
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:F. Stephen Hodi
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Howard L. Kaufman
      affiliation:
            name:Rutgers Cancer Institute of New Jersey
            address:
               name:Rutgers Cancer Institute of New Jersey, New Brunswick, USA
               type:PostalAddress
            type:Organization
      name:Jon M. Wigginton
      affiliation:
            name:MacroGenics, Inc.
            address:
               name:MacroGenics, Inc., Rockville, USA
               type:PostalAddress
            type:Organization
      name:Jedd D. Wolchok
      affiliation:
            name:Memorial Sloan Kettering Cancer Center
            address:
               name:Memorial Sloan Kettering Cancer Center, New York, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
      name:Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
      name:Rutgers Cancer Institute of New Jersey, New Brunswick, USA
      name:MacroGenics, Inc., Rockville, USA
      name:Memorial Sloan Kettering Cancer Center, New York, USA

External Links {🔗}(449)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Backbone.js
Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.26s.

LINK . SPRINGER . COM {}